1. Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. (6th February 2022) Authors: Zhou, Amy; Kong, Tim; Fowles, Jared S.; Jung, Chun‐Ling; Allen, Maggie J.; Fisher, Daniel A. C.; Fulbright, Mary; Nemeth, Elizabeta; Ganz, Tomas; Oh, Stephen T. Journal: British journal of haematology Issue: Volume 197:Number 4(2022) Page Start: e49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗